ARDX
ARDELYX, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.20
+2.24%Price chart
Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22
Key dataOct 22, 2026
Open$3.13
From 52W high−59.95%
Volume2.72M
Market cap$826.20M
P/E (TTM)—
P/S (TTM)1.8x
Div yield—
Key dataOct 22, 2026
Open
$3.13
From 52W high
−59.95%
Volume
2.72M
Market cap
$826.20M
ValuationView details →
P/E (Fwd)
47.7x
EV/EBITDA
−32.4x
P/E (TTM)
—
RSI (14)
38.5
MomentumView details →
1D Return
+2.24%
YTD Return
−45.88%
SummaryUpdated Jun 1, 2026
Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company founded in 2007 and headquartered in Waltham, Massachusetts. Originally incorporated as Nteryx, Inc., the company changed its name to Ardelyx in June 2008 and went public in 2014. Ardelyx has evolved from a development-stage biotechnology company into a commercial-stage organization with two FDA-approved products addressing unmet medical needs in gastrointestinal and kidney-related conditions. The company has successfully transitioned from years of research and development losses to achieving profitability in 2024, marking a significant milestone in its corporate evolution.
Similar companies
Latest newsMore news →
A class action lawsuit alleging securities-law violations was filed against ARDELYX, INC.2d agoARDELYX, INC. announced that management will host a webcast and conference call on November 3, 2026, at 4:30 p.m. to report its third-quarter 2026 financial results.3d agoA class action lawsuit was filed against Ardelyx on behalf of investors who acquired its common stock during the stated class period.9d ago